Changes in Helicobacter pylori‐induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro‐oesophageal reflux disease
The DOI matches its Crossref record.
Abstract
Background: Several studies have shown that treatment with omeprazole leads to aggravation of Helicobacter pylori gastritis in the corpus. Whether this also applies to lansoprazole, and whether, in comparison with omeprazole, there are differences in therapy‐induced gastritis parameter changes remains unclear. Methods: In 111 patients infected with H. pylori and with gastro‐oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day. Results: In all groups the different treatments had a similar effect: in both regions of the stomach, suppression or partial elimination of H. pylori was seen. However, improvement in the inflammation was observed only in the antrum, while in the corpus most gastritis parameters worsened significantly. There was no increase in intestinal metaplasia or atrophy. Conclusion: In common with omeprazole, lansoprazole aggravates the gastritis parameters in the corpus but improves them in the antrum. Treatment with proton pump inhibitors does not result in any increase in the incidence of atrophy/intestinal metaplasia. However, as gastritis predominating in the corpus seems to be associated with an elevated carcinogenic risk, consideration should be given to prophylactic H. pylori eradication therapy before initiating proton pump inhibitor treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Malfertheiner, P., Megraud, F., O'Morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, T., Vakil, N., Kuipers, E. J., et al. (2007) · Gut · doi:10.1136/gut.2006.101634 · Cited by 2,240
Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, A. P. S., Jones, R., Axon, A., Graham, D. Y., Tytgat, G., & The European Helicobacter Pylori Study Group (EHPSG) (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01169.x · Cited by 1,237
El–Omar, E. M., Oien, K., Murray, L. S., El–Nujumi, A., Wirz, A., Gillen, D., Williams, C., Fullarton, G., & McColl, K. E. L. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70410-0 · Cited by 336
Safety of the long-term use of proton pump inhibitors
Thomson, A. B. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i19.2323 · Cited by 315
Proton-pump inhibitors: understanding the complications and risks
Malfertheiner, P., Kandulski, A., & Venerito, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.117 · Cited by 297
Metadata
- Authors
- Stolte, Meining, Schmitz, Alexandridis, & Seifert
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1998-03
- Volume
- 12
- Issue
- 3
- Pages
- 247-253
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2081391457
- Cited by
- 106
- References
- 0
- FWCI
- 16.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in Helicobacter pylori‐induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro‐oesophageal reflux disease. https://app.cochat.ai/papers/10.1046/j.1365-2036.1998.00310.x
- The paper
- Stolte, Meining, Schmitz, Alexandridis, & Seifert. (1998). Changes in Helicobacter pylori‐induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro‐oesophageal reflux disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.1998.00310.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.